Dual PI3K/mTOR Inhibition and Therapeutic Targets in Uterine Sarcoma

Share this content:
Phospho-S6S240 (p-S6S240) expression positively correlates with poor prognosis in uterine sarcoma, and PI3K/mTOR inhibition may be effective.
Phospho-S6S240 (p-S6S240) expression positively correlates with poor prognosis in uterine sarcoma, and PI3K/mTOR inhibition may be effective.

Phospho-S6S240 (p-S6S240) expression positively correlates with poor prognosis in uterine sarcoma, and PI3K/mTOR inhibition may be an effective strategy for targeting p-S6S240-expressing disease, according to a study published in Clinical Cancer Research.1

Uterine sarcoma is a rare but aggressive group of cancers, of which leiomyosarcoma is the most common. PI3K/mTOR signaling is implicated in leiomyosarcoma, though mTOR inhibition was shown to be an ineffective treatment. Prognostic markers and new targets are needed to improve the poor outcomes of these cancers.

For this study, researchers evaluated the expression of 6 potential targets in 288 uterine sarcoma samples, 15 smooth muscle tumors, 52 benign tumors, and 41 normal samples.

Of all 6 evaluated markers, p-S6S240 expression was linked to inferior progression-free survival, recurrence, and likelihood of being higher-grade for all malignant tumors.

Based on these results, the researchers developed patient-derived xenograft (PDX) models to determine whether dual PI3K/mTOR inhibition would be effective against p-S6S240-expressing cancers. The models showed that p-S6S240-expressing tumors would respond to such inhibition with the dual inhibitor, BEZ235.

RELATED: Cyclophosphamide Reduction in Rhabdomyosarcoma

The authors concluded that p-S6S240-expression predicts poor prognosis, though sarcomas expressing p- S6S240 are likely to respond to dual PI3K/mTOR inhibition.

Reference

  1. Cuppens T, Annibali D, Coosemans A, et al. Potential targets' analysis reveals dual PI3K/mTOR pathway inhibition as a promising therapeutic strategy for uterine leiomyosarcomas—an ENITEC Group initiative. Clin Cancer Res. 2017 Feb 23. doi: 10.1158/1078-0432.CCR-16-2149 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters